FTH (Faeth Therapeutics) OCF Margin %: 0.00% (As of Mar. 2026)


FTH Faeth Therapeutics Inc FTH
21 GF Score
Price $24.96
! 2 Warning Signs
View Full Analysis

What is Faeth Therapeutics OCF Margin %?

Faeth Therapeutics FTH +0.70% 21 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates FTH with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, Faeth Therapeutics ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Faeth Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-10.73 Mil. Faeth Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Faeth Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Faeth Therapeutics's current OCF Yield % is -3.81%.

The historical rank and industry rank for Faeth Therapeutics's OCF Margin % or its related term are showing as below:


FTH's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Faeth Therapeutics OCF Margin % Related Terms

Faeth Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Faeth Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Faeth Therapeutics OCF Margin % Chart

Faeth Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Faeth Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FTH
21GF Score
Faeth Therapeutics Inc FTH
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faeth Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Faeth Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-20.453/0
= %

Faeth Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-10.733/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Faeth Therapeutics (FTH) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Faeth Therapeutics and its competitors. According to the industry distribution chart, Faeth Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry.
Is Faeth Therapeutics' OCF Margin % too high?
Faeth Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Faeth Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Faeth Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Faeth Therapeutics' OCF Margin % compare to NEUP and KYNB?
According to the Biotechnology industry distribution chart, Faeth Therapeutics ranks #999999 out of 959 companies for OCF Margin %. This places Faeth Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Faeth Therapeutics and its competitors. Faeth Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faeth Therapeutics stock overvalued right now?
Faeth Therapeutics (FTH) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Faeth Therapeutics' overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Faeth Therapeutics (FTH), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Faeth Therapeutics Business Description

Address 701 Tillery Street No. 12, No.1010, Austin, TX, USA, 78702
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
21GF Score

Get the complete analysis for FTH

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.96
Price